Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.60 |
| ▸ | CA9 | Q16790 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NQO1 | P15559 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9545054 | 0.85 | KDM4E (0.69) | POLBKDM4EALDH1A1TSHRMEN1 | |
| SCHEMBL10638322 | 0.84 | NQO1 (0.73) | CA12CA9KDM4ETP53ALDH1A1 | |
| SCHEMBL16231548 | 0.84 | KDM4E (0.49) | CA12CA9POLBKDM4ETP53 | |
| SCHEMBL2028248 | 0.82 | KDM4E (0.51) | CA12CA9KDM4ETP53ALDH1A1 | |
| SCHEMBL28719517 | 0.81 | NQO1 (0.55) | CA12CA9POLBTP53ALDH1A1 | |
| SCHEMBL590825 | 0.81 | KDM4E (0.76) | CA12CA9POLBKDM4ETP53 | |
| SCHEMBL29785070 | 0.81 | KDM4E (0.76) | CA12CA9POLBKDM4ETP53 | |
| SCHEMBL15873593 | 0.81 | CA12 (0.59) | CA12CA9POLBKDM4ETP53 | |
| SCHEMBL15842922 | 0.80 | KDM4E (0.54) | KDM4ETP53ALDH1A1NQO1TSHR | |
| SCHEMBL3366386 | 0.80 | CA12 (0.56) | CA12CA9POLBMTORKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4247968-A1 | USE OF DEXTRAMER IN SINGLE CELL ANALYSIS | Becton, Dickinson and Company (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116615556-A | Use of DEXTRAMER in single cell assays | 贝克顿迪金森公司 | 2023-08-18 | — | — | CN | claimed |
| WO-2022109339-A1 | USE OF DEXTRAMER IN SINGLE CELL ANALYSIS | BECTON, DICKINSON AND COMPANY (US) | 2022-05-27 | — | — | WO | claimed |
| US-20220064226-A1 | Panel comprising Borrelia MHC multimers | IMMUDEX APS (DK) | 2022-03-03 | — | — | US | claimed |
| EP-2516669-A2 | ENZYME ASSAYS ON A DROPLET ACTUATOR | Advanced Liquid Logic, Inc. (US) | 2012-10-31 | — | — | EP | claimed |
| WO-2011084703-A2 | ENZYME ASSAYS ON A DROPLET ACTUATOR | ADVANCED LIQUID LOGIC, INC. (US) | 2011-07-14 | — | — | WO | claimed |
| WO-2026087501-A1 | ANTIGEN MULTIMERS FOR DETECTION OF ANTIGEN-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS | IMMUDEX APS (DK) | 2026-04-30 | — | — | WO | disclosed |
| EP-4709743-A1 | MHC CLASS I MOLECULES | Immudex ApS (DK) | 2026-03-18 | — | — | EP | disclosed |
| US-20250382335-A1 | Panel comprising Borrelia MHC multimers | IMMUDEX APS (DK) | 2025-12-18 | — | — | US | disclosed |
| EP-4643131-A2 | COMPOSITIONS AND METHODS FOR THE DETECTION OF MYCOPLASMA | IDEXX LABORATORIES, INC. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250231185-A1 | Coronavirus T Cell Epitopes, Megapools and Uses Thereof | LA JOLLA INST FOR IMMUNOLOGY (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2025125477-A1 | MHC CLASS I MOLECULE MATCHED NEGATIVE CONTROL REAGENTS | IMMUDEX APS (DK) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025109111-A1 | IMMUNE CELL ACTIVATING MULTIMERS | IMMUDEX APS (DK) | 2025-05-30 | — | — | WO | disclosed |
| CN-101612029-A | Image acquiring method and device | FUJIFILM CORP | 2009-12-30 | — | — | CN | disclosed |
| EP-1943257-A2 | FIBROBLAST ACTIVATION PROTEIN INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7176185-B2 | Short peptide carrier system for cellular delivery of agent | TSRL, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| WO-2006125227-A2 | FIBROBLAST ACTIVATION PROTEIN INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20050208140-A1 | Short peptide carrier system for cellular delivery of agent | TSRL, INC. | 2005-09-22 | — | — | US | disclosed |
| US-5364764-A | Immunoassay of HIV | MOLECULAR PROBES, INC. (US) | 1994-11-15 | — | — | US | disclosed |
| US-5262545-A | Used to study transcriptional control sequence in the field of endocrinology, microbiology, virology, genetics and oncology | MOLECULAR PROBES, INC. (US) | 1993-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050208140-A1 | Short peptide carrier system for cellular delivery of agent | SLC43A1, DNPEP, LNPEP | CA12 152/4885CA9 1296/4885POLB 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.